SHAREHOLDERS' EQUITY (Details) $ / shares in Units, $ in Thousands					12 Months Ended
		Feb. 12, 2021 USD ($) $ / shares shares	Feb. 09, 2021 USD ($) $ / shares shares	May 20, 2020 $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock offering, shares sold (in shares)		8,750,000	5,650,000
Stock offering, purchase price (in dollars per share) | $ / shares		$ 3.92	$ 2.48
Stock offering, gross proceeds | $		$ 34,300	$ 14,000
Stock offering, net proceeds | $		$ 32,200	$ 13,100
Issuance of common stock in connection with Zyla Merger (in shares)				6,400,000
Warrants exercised (in shares)					1,200,000	1,500,000
Common shares issued (in shares)					1,200,000	1,500,000
Warrants outstanding (in shares) | $					$ 400
Options exercised during period (in shares)					72,750	0
Proceeds from issuance of common stock | $					$ 44,861	$ 88
Zyla Life Sciences
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Merger exchange ratio				2.5
Zyla Life Sciences | Iroko | Warrant Agreements
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise aggregate ownership percentage maximum threshold				49.00%
Exercise aggregate ownership percentage term				18 months
Zyla Life Sciences | Money market funds | Zyla Life Sciences
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price, number of shares outstanding, per share (in dollars per share) | $ / shares				$ 0.0016
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of awards as percentage of the fair value of common stock (at least)					85.00%
Shares sold (in shares)					3,929	45,682
Weighted average purchase price of shares sold (in dollars per share) | $ / shares					$ 1.40	$ 1.91
Proceeds from shares sold | $					$ 0	$ 100
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of common stock | $					$ 200
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock in connection with Zyla Merger (in shares)	[1]					6,370,000
Shares sold (in shares)	[1]				4,000	46,000
Options exercised during period (in shares)	[1]				73,000

[1] Adjusted to reflect the 1-for-4 reverse stock split effected on May 18, 2021.